Repligen Corp. (RGEN) intrinsic value & 10-year financials
Repligen Corp. (RGEN) has a Graham intrinsic value of $28.57 per share. At $175.42 on Oct 17, 2026, the stock trades 514% above that value. Over the last 10 fiscal years revenue grew 24.3% a year to $738.3M, with an average return on invested capital of 6.4%.
- Graham intrinsic value
- $28.57
- Share price (Oct 17, 2026)
- $175.42
- Price vs Graham value
- 514% above
- Market cap
- $9.9M
- Revenue (FY2025)
- $738.3M
- Revenue growth (10-yr CAGR)
- 24.3%
- ROIC (10-yr avg)
- 6.4%
- Free cash flow (FY2025)
- $93.9M
RGEN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $738.3M | $48.9M | $0.86 | $93.9M | 7.5% | 2.1% |
| FY2024 | $634.4M | -$25.5M | -$0.46 | $149.7M | -5.5% | -2.1% |
| FY2023 | $638.8M | $41.6M | $0.74 | $77.7M | 8.5% | 2.5% |
| FY2022 | $801.5M | $186.0M | $3.24 | $87.2M | 28.0% | 13.8% |
| FY2021 | $670.5M | $128.3M | $2.24 | $51.9M | 24.9% | 13.4% |
| FY2020 | $366.3M | $59.9M | $1.11 | $40.2M | 19.1% | 10.0% |
| FY2019 | $270.2M | $21.4M | $0.44 | $48.7M | 13.4% | 5.3% |
| FY2018 | $194.0M | $16.6M | $0.00 | $22.1M | 13.4% | — |
| FY2017 | $141.2M | $28.4M | $0.00 | $12.0M | 9.9% | — |
| FY2016 | $104.5M | $11.7M | $0.00 | $3.2M | 15.3% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
REPLIGEN CORP is a consistent compounder, expanding top-line revenue at 24.3% annually over the past decade.
REPLIGEN CORP has historically struggled to out-earn its cost of capital, averaging just 6.4% ROIC.
Over the decade, REPLIGEN CORP shows that management has aggressively returned capital to shareholders by retiring 100.0% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, REPLIGEN CORP is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $28.57 per share.